CN112218661A - 金属-碘塞罗宁 - Google Patents

金属-碘塞罗宁 Download PDF

Info

Publication number
CN112218661A
CN112218661A CN201980028465.9A CN201980028465A CN112218661A CN 112218661 A CN112218661 A CN 112218661A CN 201980028465 A CN201980028465 A CN 201980028465A CN 112218661 A CN112218661 A CN 112218661A
Authority
CN
China
Prior art keywords
complex
metal
biologically active
active moiety
another embodiment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201980028465.9A
Other languages
English (en)
Chinese (zh)
Inventor
约翰·D·普赖斯
托马斯·皮卡里埃洛
迈克尔拉·E·穆哈雷
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Synthonics Inc
Original Assignee
Synthonics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Synthonics Inc filed Critical Synthonics Inc
Publication of CN112218661A publication Critical patent/CN112218661A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/547—Chelates, e.g. Gd-DOTA or Zinc-amino acid chelates; Chelate-forming compounds, e.g. DOTA or ethylenediamine being covalently linked or complexed to the pharmacologically- or therapeutically-active agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/30—Zinc; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/34—Copper; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/52—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an inorganic compound, e.g. an inorganic ion that is complexed with the active ingredient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F3/00—Compounds containing elements of Groups 2 or 12 of the Periodic Table
    • C07F3/003—Compounds containing elements of Groups 2 or 12 of the Periodic Table without C-Metal linkages

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Inorganic Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pyridine Compounds (AREA)
CN201980028465.9A 2018-04-04 2019-04-04 金属-碘塞罗宁 Pending CN112218661A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862652705P 2018-04-04 2018-04-04
US62/652,705 2018-04-04
PCT/US2019/025725 WO2019195513A1 (en) 2018-04-04 2019-04-04 Metallo-liothyronine

Publications (1)

Publication Number Publication Date
CN112218661A true CN112218661A (zh) 2021-01-12

Family

ID=68101148

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201980028465.9A Pending CN112218661A (zh) 2018-04-04 2019-04-04 金属-碘塞罗宁

Country Status (9)

Country Link
US (2) US11712426B2 (https=)
EP (1) EP3773733B1 (https=)
JP (1) JP7535993B2 (https=)
KR (1) KR20200143701A (https=)
CN (1) CN112218661A (https=)
AU (1) AU2019247217A1 (https=)
BR (1) BR112020020403A8 (https=)
CA (1) CA3096199A1 (https=)
WO (1) WO2019195513A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11712426B2 (en) * 2018-04-04 2023-08-01 Synthonics, Inc. Metallo-liothyronine
JP2022030705A (ja) * 2020-08-07 2022-02-18 日本曹達株式会社 チアベンダゾール含有配位高分子

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007050181A2 (en) * 2005-10-24 2007-05-03 Synthonics, Inc. Metal coordinated compositions
CN103313720A (zh) * 2010-11-08 2013-09-18 辛索尼克斯公司 用于调节生物活性剂的性质的含铋化合物

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1298613B1 (it) * 1998-03-10 2000-01-12 Bracco Spa Chelati complessi di manganese ad alta relassivita' in siero
JP2003261683A (ja) * 2002-03-06 2003-09-19 Nof Corp 中性（ベンゼン−１，２，４，５−テトラチオラート）金属錯体ポリマー、その製造方法および用途
US7799937B2 (en) 2004-10-25 2010-09-21 Synthonics, Inc. Metal coordinated compositions
AU2013205471B2 (en) 2005-10-24 2016-02-11 Synthonics, Inc. Metal coordinated compositions
JP5162758B2 (ja) * 2006-03-02 2013-03-13 大学共同利用機関法人自然科学研究機構 マイクロチャンネルリアクター
EP2536408A1 (en) * 2010-02-16 2012-12-26 Wockhardt Research Centre Efflux pump inhibitors
JP6183763B2 (ja) * 2014-05-02 2017-08-23 国立研究開発法人物質・材料研究機構 有機／ヘテロ金属ハイブリットポリマー、その合成方法、有機／ヘテロ金属ハイブリットポリマーの膜、有機／マルチ金属ハイブリットポリマー、その合成方法、及び有機／マルチ金属ハイブリットポリマーの膜
CA2951923A1 (en) * 2014-06-18 2015-12-23 Thetis Pharmaceuticals Llc Mineral amino-acid complexes of active agents
JP6838268B2 (ja) * 2015-10-21 2021-03-03 コニカミノルタ株式会社 光変換材料、光変換フィルム、及び発光素子
US11712426B2 (en) * 2018-04-04 2023-08-01 Synthonics, Inc. Metallo-liothyronine

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007050181A2 (en) * 2005-10-24 2007-05-03 Synthonics, Inc. Metal coordinated compositions
CN103313720A (zh) * 2010-11-08 2013-09-18 辛索尼克斯公司 用于调节生物活性剂的性质的含铋化合物

Also Published As

Publication number Publication date
JP7535993B2 (ja) 2024-08-19
EP3773733A4 (en) 2022-05-25
US20230381126A1 (en) 2023-11-30
EP3773733A1 (en) 2021-02-17
US11712426B2 (en) 2023-08-01
CA3096199A1 (en) 2019-10-10
AU2019247217A1 (en) 2020-11-26
EP3773733C0 (en) 2025-11-12
BR112020020403A8 (pt) 2021-04-13
EP3773733B1 (en) 2025-11-12
KR20200143701A (ko) 2020-12-24
BR112020020403A2 (pt) 2021-03-23
JP2021521268A (ja) 2021-08-26
US20210046032A1 (en) 2021-02-18
WO2019195513A1 (en) 2019-10-10

Similar Documents

Publication Publication Date Title
DK2459176T3 (en) Crystallization process and bioavailability
DK2531200T3 (en) COSTALLIZATION PROCEDURE AND BIOTA ACCESSIBILITY
US20230381126A1 (en) Metallo-liothyronine
ZA200401741B (en) Novel chromium (iii)alpha amino acid complexes
US9402861B2 (en) Polyamine-dihydroxybenzoic acid conjugate hydrogels as iron chelators
Song et al. A cross-linked polymeric micellar delivery system for cisplatin (IV) complex
KR20040068312A (ko) 인산의 흡착제
JP2001503457A (ja) 食物ホスフェート又はオキサレート吸収を低下させるための水溶性ポリマー
CA2658338A1 (en) Amine dendrimers
NO163693B (no) Fremgangsmaate for fremstilling av terapeutisk aktive forbindelser av platina.
AU2014219129A1 (en) Caged platinum nanoclusters for anticancer chemotherapeutics
KR100807358B1 (ko) 암조직 선택성과 생분해성을 갖는 고리형 삼합체포스파젠-백금(ｉｉ) 착물 컨쥬게이트 항암제 및 그 제조방법
Park et al. Ionic complex of risedronate with positively charged deoxycholic acid derivative: evaluation of physicochemical properties and enhancement of intestinal absorption in rats
JP2016518422A (ja) 癌の治療および予防のための（＋）‐カテキンおよびアミノ酸の複合体を含む組成物
CN110787303B (zh) 一种Pt与巯基化合物的加合物Pt-SR、制备及应用
US20220332876A1 (en) Hydrophilic-hydrophobic copolymer carrying short chain fatty acid ester
JP2024500539A (ja) バナジウム化合物を用いた疼痛の治療方法
Minzanova et al. Scientific grounds and process aspects for the production of polygalacturonate with Ca2+ and Fe2+ ions
CN120504625A (zh) 一种靶向pd-l1的小分子抑制剂及其联合光动力疗法制备的纳米颗粒、药物和应用
CN121313860A (zh) 还原肽自组装纤维-亚铁纳米复合物及其制备方法和应用
CN117503803A (zh) 一种可触发的前药纳米涂层及其应用
CN118754830A (zh) 一种可逆转肺癌顺铂耐药的纳米载药系统及其制备方法与应用
HK1171966B (en) Crystallization method and bioavailability
HK1171966A (en) Crystallization method and bioavailability

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
WD01 Invention patent application deemed withdrawn after publication
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20210112